Search Results - "Belau, A."

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR) by Sehouli, J., Chekerov, R., Reinthaller, A., Richter, R., Gonzalez-Martin, A., Harter, P., Woopen, H., Petru, E., Hanker, L.C., Keil, E., Wimberger, P., Klare, P., Kurzeder, C., Hilpert, F., Belau, A.K., Zeimet, A., Bover-Barcelo, I., Canzler, U., Mahner, S., Meier, W.

“…The combination of carboplatin and topotecan in platinum-sensitive relapsed ovarian cancer could not improve progression-free survival or overall survival…”
Get full text

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer by Sinn, B.V., von Minckwitz, G., Denkert, C., Eidtmann, H., Darb-Esfahani, S., Tesch, H., Kronenwett, R., Hoffmann, G., Belau, A., Thommsen, C., Holzhausen, H.J., Grasshoff, S.T., Baumann, K., Mehta, K., Dietel, M., Loibl, S.

“…Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response…”
Get full text

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer by Lee, C.K., Simes, R.J., Brown, C., Gebski, V., Pfisterer, J., Swart, A.-M., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Schauer, C., Pisano, C., Parma, G., Baumann, K., Ledermann, J.A., Pujade-Lauraine, E., Bentley, J., Kristensen, G., Belau, A., Nankivell, M., Canzler, U., Lord, S.J., Kurzeder, C., Friedlander, M.

“…Patients with platinum-sensitive recurrent ovarian cancer have variable prognosis and survival. We extend previous work on prediction of progression-free…”
Get full text

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study by Sehouli, J., Runnebaum, I.B., Fotopoulou, C., Blohmer, U., Belau, A., Leber, H., Hanker, L.C., Hartmann, W., Richter, R., Keyver-Paik, M.D., Oberhoff, C., Heinrich, G., du Bois, A., Olbrich, C., Simon, E., Friese, K., Kimmig, R., Boehmer, D., Lichtenegger, W., Kuemmel, S.

“…Simultaneous adjuvant platinum-based radiochemotherapy in high-risk cervical cancer (CC) is an established treatment strategy. Sequential paclitaxel (Taxol)…”
Get full text

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology) by Mustea, A., Koensgen, D., Belau, A., Sehouli, J., Lichtenegger, W., Schneidewind, L., Sommer, H., Markmann, S., Scharf, J. P., Ehmke, M., Ledwon, P., Braicu, I., Zygmunt, M., Koehler, G.

“…Purpose The management of high-risk endometrial cancer (HREC) remains controversial. We conducted a prospective multicenter phase-II clinical trial to evaluate…”
Get full text

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR by Pfisterer, J, du Bois, A, Sehouli, J, Loibl, S, Reinartz, S, Reuß, A, Canzler, U, Belau, A, Jackisch, C, Kimmig, R, Wollschlaeger, K, Heilmann, V, Hilpert, F

“…Background: Abagovomab is a murine anti-idiotypic antibody against the antigen CA-125 which has been shown to elicit humoral and cellular immune responses…”
Get full text

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC–IV (AGO-OVAR protocol OVAR-8) by du Bois, A., Belau, A., Wagner, U., Pfisterer, J., Schmalfeldt, B., Richter, B., Staehle, A., Jackisch, C., Lueck, H.J., Schroeder, W., Burges, A., Olbricht, S., Elser, G.

“…A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine…”
Get full text

8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER) by Sehouli, J, Oskay-Özcelik, G, Stengel, D, Harter, P, Kurzeder, C, Belau, A, Markmann, S, Lorenz, R, Mueller, L, Lichtenegger, W

Get full text

Practicability of magnetoencephalography-guided neuronavigation by FIRSCHING, R, BONDAR, I, HEINZE, H.-J, HINRICHS, H, HAGNER, T, HEINRICH, J, BELAU, A

“…Magnetoencephalography (MEG) is a noninvasive option for localizing electroneurophysiological activity on the human cortex. The purpose of this study was to…”
Get full text

176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) by Nagao, S., Harter, P., Leary, A., Cropet, C., Pignata, S., Fujiwara, K., Gonzalez Martin, A.J., Bogner, G., Vergote, I., Colombo, N., Maenpaa, J., Selle, F., Schmalfeldt, B., Scambia, G., Guerra Alia, E.M., Lefeuvre-Plesse, C., Belau, A., Lortholary, A., Gropp-Meier, M., Pujade-Lauraine, E., Ray-Coquard, I.

Get full text

LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) by Ray-Coquard, I.L., Leary, A., Pignata, S., Cropet, C., Martin, A.J. Gonzalez, Bogner, G., Yoshida, H., Vergote, I.B., Colombo, N., Maenpaa, J., Selle, F., Schmalfeldt, B., Scambia, G., Alia, E.M. Guerra, Lefeuvre-Plesse, C., Belau, A., Lortholary, A., Gropp-Meier, M., Pujade-Lauraine, E., Harter, P.

Get full text

5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients by Loibl, S, Pfisterer, J, Wimberger, P, Kurzeder, C, Du Bois, A, Sehouli, J, Belau, A, Burchardi, N, Vergote, I, Wagner, U

Get full text

8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy by Sinn, B.V., von Minckwitz, G., Denkert, C., Eidtmann, H., Darb-Esfahani, S., Belau, A., Kronenwett, R., Holzhausen, H., Mehta, K., Loibl, S.

Get full text

P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab by Eidtmann, H, Kittel, K, Rezai, M, Tesch, H, Ulmer, HU, Stirnberg, S, Belau, A, Mau, C, Stickeler, E, Schrader, I, Fasching, P, Salat, CT, Abdallah, A, Holms, F, Schwedler, K, Nekljudova, V, Loibl, S, von, Minckwitz G

“…Abstract Background: Bevacizumab has been reported to increase the risk of surgical complications, especially in pts treated with neoadjuvant chemotherapy…”
Get full text

Response rate and toxicity of primary concomitant radio-chemotherapy in locally advanced cervical cancer: Results of an open prospective, multicenter phase II study of the NOGGO by Mustea, A., Belau, A., Sehouli, J., Drzewiecki, K., Eichbaum, M. H. R., Bartz, K., Angelidou, E., Saegner, S., Langenbruch, M. O., Ledwon, P., Zygmunt, M., Koehler, G., Koensgen, D.

“…Abstract only…”
Get full text

Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO by Koensgen, D., Belau, A., Sehouli, J., Sommer, H. L., Bartz, K., Markmann, S., Schneidewind, L., Scharf, J. P., Ehmke, M., Stengel, D., Ledwon, P., Guba, H., Zygmunt, M., Koehler, G., Mustea, A.

“…Abstract only…”
Get full text

Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup Study by Sehouli, J., Blohmer, J. U., Kuemmel, S., Runnebaum, I. B., Hartmann, W., Richter, R., Belau, A., Leber, H., Kaufmann, M., Lichtenegger, W.

“…Abstract only…”
Get full text

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO) by Sehouli, J., Oskay-Oezcelik, G., Stengel, D., Harter, P., Kurzeder, C., Belau, A., Markmann, S., Lorenz, R., Mueller, L., Lichtenegger, W.

“…Abstract only 5553 Background: In women with platinum-resistant recurrent ovarian cancer, weekly administration of topotecan (Tw) may be equally effective, but…”
Get full text

Toxicity of adjuvant sequential chemo- and radiotherapy of high-risk endometrial carcinoma (HREC)—Results of a phase II multicenter feasibility NOGGO study by Koehler, G., Sehouli, J., Sommer, H., Blohmer, J., Bartz, K., Belau, A.

“…Abstract only 16074 Background: Isolated adjuvant radio- or chemotherapy (CHT) only reduces local or distant relapses in HREC without impact on…”
Get full text

Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients by Belau, A., Pfisterer, J., Wimberger, P., Kurzeder, C., Du Bois, A., Sehouli, J., Loibl, S., Burchardi, N., Vergote, I., Wagner, U.

“…Abstract only 5556 Background: The trifunctional antibody catumaxomab specifically binds EpCAM+ tumor cells, CD3+ T lymphocytes and accessory cells via the Fcγ…”
Get full text